KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) EBITDA Margin: 2018-2025

Historic EBITDA Margin for Adaptive Biotechnologies (ADPT) over the last 8 years, with Sep 2025 value amounting to 10.95%.

  • Adaptive Biotechnologies' EBITDA Margin rose 4175.00% to 10.95% in Q3 2025 from the same period last year, while for Sep 2025 it was -24.05%, marking a year-over-year increase of 5033.00%. This contributed to the annual value of -90.83% for FY2024, which is 4250.00% up from last year.
  • Adaptive Biotechnologies' EBITDA Margin amounted to 10.95% in Q3 2025, which was up 184.33% from -12.98% recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year EBITDA Margin high stood at 10.95% for Q3 2025, and its period low was -322.32% during Q2 2023.
  • For the 3-year period, Adaptive Biotechnologies' EBITDA Margin averaged around -84.10%, with its median value being -67.30% (2024).
  • As far as peak fluctuations go, Adaptive Biotechnologies' EBITDA Margin crashed by 20,207bps in 2023, and later skyrocketed by 27,990bps in 2024.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' EBITDA Margin stood at -162.39% in 2021, then spiked by 9,140bps to -70.99% in 2022, then crashed by 8,423bps to -155.22% in 2023, then soared by 8,393bps to -71.30% in 2024, then skyrocketed by 4,175bps to 10.95% in 2025.
  • Its EBITDA Margin was 10.95% in Q3 2025, compared to -12.98% in Q2 2025 and -56.45% in Q1 2025.